

SIRIC MONTPELLIER CANCER

“8th ANNUAL MEETING”

25 JUNE 2021



In collaboration with FHU EVOCAN & Pôle Biologie Santé



SIRIC
MONTPELLIER CANCER
Site de Recherche Intégrée sur le Cancer

evocan
Heteroclonality and Personalised Treatments in Cancer

 **M U S E**
PÔLE BIOLOGIE-SANTÉ
MONTPELLIER UNIVERSITY OF EXCELLENCE

AMGEN®







Bayer **HealthCare**









8h45 Welcome

SESSION 1

Cancer research from bench to preclinical studies in Montpellier: highlights 2020-2021

Chairman : Philippe PASERO (IGH, Montpellier) & Serge ROCHE (CRBM, Montpellier)

- 9h00** Notching up the resensitization against EGFR TKIs in lung adenocarcinoma harboring EGFR “gatekeeper” mutations
Antonio MARAVER (IRCM, Montpellier)
- 9h30** Targeting the ubiquitin-like molecule NEDD8 for therapeutic intervention
Dimitri XIRODIMAS (CRBM, Montpellier)
- 10h00** Spatial chromatin organization in normal and pathological hematopoietic cells
Eric SOLER (IGMM, Montpellier)
- 10h30** More than a crosstalk, histone marks can be drivers of the changes in splicing essential for EMT
Reini FERNANDEZ DE LUCO (IGH, Montpellier)

11h00 Coffee break

SESSION 2

Keynote lecture

Chairman : Dan FISHER (IGMM, Montpellier)

- 11h30** Cancer evolution, immune evasion and metastasis
Charles SWANTON (The Francis Crick Institute, London)

Keynote lecture

Chairman : David AZRIA (ICM, Montpellier)

- 12h00** Micron-Scale AI-driven Radiation Therapy driven Multi-Parametric Imaging
Nikolaos PARAGYIOS (Thérapanacea, Paris)

12h30 Lunch

SESSION 3

Patient involvement in cancer research

13h30 Bettina RYLL (Melanoma Patient Network Europe, Uppsala)

SESSION 4

Recent updates in clinical and translational research

Chairman :

14h00 CAR-T cells: Treatment of today, treatment of the future?

Guillaume CARTRON (CHU de Montpellier)

14h30 Untangling tumor adaptive responses to select new drug combinations

Diego TOSI (ICM, Montpellier)

15h00 xxxxxxxx

15h30 Coffee break

SESSION 5

Emerging groups of Montpellier Cancer Research

Chairman : Ula HIBNER (IGMM, Montpellier) & Claude SARDET (IRCM, Montpellier)

16h00 Using Intervention Mapping to co-create with stakeholders an intervention to facilitate return-to-work after breast cancer

Guillaume BROC (Epsilon, Montpellier)

16h20 BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Charles HERBEAUX (CHU de Montpellier, IGH)

16h40 Citrullination of RNA Polymerase II controls Transcription plasticity in Breast Cancer

Priyanka SHARMA (IRCM, Montpellier)

17h00 Understanding the immune microenvironment to improve immunotherapy for brain tumors

Alexandra GARANCHER (IRCM, Montpellier)

17h20 Closure